ABIONYX Pharma Updates on Mid-Year 2026 Financials

In a recent update, ABIONYX Pharma, a biopharmaceutical company focusing on innovations for sepsis and critical care, reported a consolidated revenue of €1.9 million for the first half of 2026. This revenue was solely generated by its subsidiary, IRIS Pharma, through contract research organization activities in ophthalmology. The company did not generate revenue from its core biopharmaceutical activities, as it continues to provide products free of charge under Compassionate Use Authorization applications.

The company reported a cash balance of €26.9 million as of June 30, 2026, a significant increase from the €3.4 million recorded in the same period last year, following a recently announced financing transaction. This financial position provides ABIONYX with visibility through the end of 2028, with additional support expected from forthcoming Research Tax Credits and France 2030 plan grants.